Drugs / PRO 2000
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00081640 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00006207 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRO 2000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006207 ↗ |
| Known as | PRO 2000 Gel | “PRO 2000 Gel is designed to be inserted into the vagina to protect women from getting HIV during sex.” NCT00081640 ↗ |
| Known as | PRO 2000/5 Gel (P) | “PRO 2000/5 Gel (P), or PRO 2000, is a vaginal microbicide that has been evaluated in Phase I safety trials in Europe and the U.S.” NCT00081640 ↗ |
| Route | Other | “Participants apply PRO 2000/5 gel intravaginally either once or twice daily for 14 days.” NCT00006207 ↗ |